Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLGM1
- Development stage
- Preclinical
- Lead developer
- Medical College of Wisconsin
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NLGM1 is a nanoliposomal formulation of the monosialoganglioside GM1 (monosialotetrahexosylganglioside), a glycosphingolipid naturally found in cell membranes. Developed primarily by researchers at the Medical College of Wisconsin, NLGM1 is being investigated for its cytoprotective and vasoprotective properties in conditions characterized by endothelial dysfunction and oxidative stress, such as AL amyloidosis, ischemic stroke, and medin-induced vascular disease. The formulation works by restoring the activity of endothelial nitric oxide synthase (eNOS), thereby increasing nitric oxide production and improving vasoreactivity. Additionally, NLGM1 acts as an antioxidant by reducing the levels of reactive oxygen species (ROS) and peroxynitrite, and by modulating the Nrf-2 stress response pathway. The nanoliposomal carrier enhances the delivery and integration of GM1 into target cell membranes compared to the free form of the ganglioside.
- Other names
- Nanoliposomal GM1GM1-nanoliposomesGM-1-nanoliposomesGM 1-nanoliposomesMonosialoganglioside-containing nanoliposomesLiposomal ganglioside GM1
02
Targets
HMOX1 (Heme oxygenase 1)NQO1NOS3 (eNOS)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on NLGM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLGM1.